PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete If Known	
Application Number	10/774,043
Filing Date	February 5, 2004
First Named Inventor	Qaber et al.
Art Unit	~~4647~~ 1614
Examiner Name	~~Unknown~~ Spivack
Attorney Docket Number	5808.04

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,307,094	12/22/1981	Hassall et al.	
		4,767,871	08/30/1988	Holmes et al.	
		4,885,023	12/05/1989	Yamaguchi et al.	
		5,180,418	01/19/1993	Pissiotas et al.	
		6,117,896	09/12/2000	Qabar et al.	
		6,372,744	04/16/2002	Qabar et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		CA 593525	03/01/1960	Clarke		
		EP 104484	04/04/1984	Koybayashi et al.		
		JP 59-172491	09/29/1984	Nagano et al.		
		DD 228812	10/23/1985	Meyer et al.		
		JP 01-121290	05/12/1989	Yamaguchi et al.		
		DE 3813884	11/16/1989	Dorfmeister et al.		
		EP 370955	05/03/1990	Pissiotas et al.		
		WO 93/16103	08/19/1993	Flynn et al.		
		WO 93/23403	11/25/1993	Flynn et al.		
		EP 599 444	06/01/1994	Karanewsky et al.		
		WO 95/33751	12/14/1995	Dolle et al.		
		WO 95/35308	12/28/1995	Bemis et al.		
		WO 96/19483	06/27/1996	Dimaio et al.		
		EP 743 319	11/20/1996	Robl et al.		

Examiner Signature	/Phyllis Spivack/	Date Considered	05/23/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete If Known	
Application Number	10/774,043
Filing Date	February 5, 2004
First Named Inventor	Qaber et al.
Art Unit	1617
Examiner Name	Unknown
Attorney Docket Number	5808.04

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		ADAM et al., "Determination of the Triplet Lifetimes of 1,3-Cyclopentadiyl Biradicals Derived from the Photodenitrogenation of Azoalkanes with Time-Resolved Photoacoustic Calorimetry," *J. Org. Chem. 58*: 1477-1482, 1993.	
		ASPINALL et al., "Enhanced Discrimination by Aza Dienophiles over their Olefinic Counterparts for the Diastereotopic Faces of Methyl (*E,E*)-5-(2', 3', 4', 6'-Tetra-O-acetyl-β-D-glucopyranosyloxy)penta-2,4-dienoate," *Tetrahedron Letters 35*(20): 3397-3400, 1994.	
		ATTWOOD et al., "The Design and Synthesis of the Angiotensin Converting Enzyme Inhibitor Cilazapril and Related Bicyclic Compounds," *J. Chem. Soc. Perkin Trans. I*: 1011-1019, 1986.	
		BALDWIN et al., "Synthesis Of A Bicyclic γ-Lactam Dipeptide Analogue," *Heterocycles 34*(5): 903-906, 1992.	
		BAUER et al., "Mehrfach ungesättigte Radikalkationen: Regio- und Stereochemie der oxidativen Dimerisierung von Heptafulvenen," *Chem. Ber. 117*: 609-626, 1984.	
		BAYDAR et al., "Acyl Analogues of the Ene Reaction," *J. Chem. Soc. Chem. Comm.* pp. 650-652, 1976.	
		BERNABEU et al., "(2E)-4-Methoxy-2,4-pentadienamides as New Dienes in the Diels-Alder Reaction," *Tetrahedron Letters 37*(20): 3595-3598, 1996.	
		BIRD et al., "Activation of Nuclear Transcription Factor NF-κB by Interleukin-1 Is Accompanied by Casein Kinase II-mediated Phosphorylation of the p65 Subunit," *The Journal of Biological Chemistry 272*(51): 32606-32612, 1997.	
		BOYD et al., "The Chemistry of *N*-Substituted 3-Amino-1*H*-2-benzopyran-1-ones and 5-Amino-2,3-dihydrofuran-2-ones. Ene-type Reactions involving Transfer of Acyl Groups. X-Ray Crystal Structure of *cis*-3,4-Dihydro-4-morpholinocarbonyl-3-*p*-nitrophenyl-1*H*-2-benzopyran-1-one," *J. Chem Soc. Perkin Trans. 1*: pp. 1351-1360, 1978.	
		BUTT et al., "Trancription Factors as Drug Targets: Opportunities for Therapeutic Selectivity," *Gene Expression 4*: 319-336, 1995.	
		COLOMBO et al., "Conformationally Constrained Dipeptides: Synthesis of 7,5- and 6,5-Fused Bicyclic Lactams by Stereoselective Radical Cyclizations," *Tetrahedron Letters 36*(4): 625-628, 1995.	
		COLOMBO et al., "Synthesis of 7,5-Fused Bicyclic Lactams by Stereoselective Radical Cyclization," *Tetrahedron Letters 35*(23): 4031-4034, 1994.	
		COWLEY et al., "Regio- and Stereo-selective Intermolecular Interceptions of a Conjugated *N*-Acylhydrazonium Ion," *Tetrahedron Letters 35*(42): 7853-7856, 1994.	
		GOLDSCHMIDT et al., "Activation Of Electron Deficient Cycloheptatrienes By Tricarbonyliron Complexation," *Tetrahedron Letters 31*(46): 6711-6712, 1990.	

Examiner Signature	/Phyllis Spivack/	Date Considered	05/23/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is contains a valid OMB number.

Substitute for form 1449A/PTO	Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/774,043
	Filing Date	February 5, 2004
	First Named Inventor	Qaber et al.
	Art Unit	1617
(use as many sheets as necessary)	Examiner Name	Unknown
Sheet 3 of 4	Attorney Docket Number	5808.04

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		GRANGIER et al., "Reactivity of Nucleophilic Uracil Derivatives," *J. Heterocyclic Chem. 31*: 1707-1714, 1994.	
		HASSALL et al., "The Design and Synthesis of New Triazolo, Pyrazolo-, and Pyridazo-pyridazine Derivatives as Inhibitors of Angiotensin Converting Enzyme," *J. Chem. Soc. Perkin Trans. I*: 155-164, 1984.	
		JUNGHEIM et al., "Bicyclic Pyrazolidinones, A New Class Of Antibacterial Agent Based On The β-Lactam Model," *Tetrahedron Letters 28*(3): 285-288, 1987.	
		LI et al., "Conformationally Restricted Peptide Mimetics: The Incorporation of 6,5-Bicyclic Lactam Ring Skeletons into Peptides," *J. Org. Chem. 60*: 8155-8170, 1995.	
		LOMBART et al., "Synthesis of Enantiopure α,ω-Diamino Dicarboxylates and Azabicycloalkane Amino Acids by Claisen Condensation of α-[*N*-(Phenylfluorenyl)amino] Dicarboxylates," *The Journal of Organic Chemistry 59*(21): 6147-6149, 1994.	
		MATHEWS et al., "Active-Site Mimetic of Thrombin," *Acta Crystallographica Section D. Biological Crystallography D51*(4): 550-559, July 1, 1995.	
		MAYER et al., "A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies," *Journal of Computer-Aided Molecular Design 1: 3-16, 1987.*	
		MOYNAGH et al., "Interleukin-1 activates transcription factor NFκB in glial cells," *Biochem. J. 294*: 343-347, 1993.	
		MUELLER et al., "Synthesis of 6,5-Fused Bicyclic Lactams as Potential Dipeptide β-Turn Mimetics," *Tetrahedron Letters 35*(24): 4091-4092, 1994.	
		NAGAI et al., "Bicyclic Turned Dipeptide (BTD) as a β-Turn Mimetic; its Design, Synthesis and Incorporation into Bioactive Peptides," *Tetrahedron 49*(17): 3577-3592, 1993.	
		ROBERTS et al., "Asymmetric Synthesis of Two-Residue Modules Designed for Mimicry of Beta Strands," *Tetrahedron Letters 36*(5): 691-694, 1995.	
		ROBL et al., "Dual Metalloprotease Inhibitors. 6. Incorporation of Bicyclic and Substituted Monocyclic Azepinones as Dipeptide Surrogates in Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitors," *J. Med. Chem. 39*: 494-502, 1996.	
		ROBL, "Peptidomimetic Synthesis: Utilization of N-Acyliminium Ion Cyclization Chemistry in the Generation of 7,6- and 7,5-Fused Bicyclic Lactams," *Tetrahedron Letters 35*(3): 393-396, 1994.	
		RUBARTELLI et al., "Interleukin Iβ and thioredoxin are secreted through a novel pathway of secretion," *Biochem. Soc. Trans. 19*: 255-259, 1991.	

Examiner Signature	/Phyllis Spivack/	Date Considered	05/23/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(use as many sheets as necessary)* Sheet 4 of 4	***Complete if Known***	
	Application Number	10/774,043
	Filing Date	February 5, 2004
	First Named Inventor	Qaber et al.
	Art Unit	1617
	Examiner Name	Unknown
	Attorney Docket Number	5808.04

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		SEGUCHI et al., "Ready Alcoholysis of the Cycloadducts (Urazole) of 4-Phenyl-1,2,4-triazole-3,5-dione by Solvent-assisted Backbone Participation," *J. Chem. Soc. Perkin Trans. 1:* pp. 2883-2884, 1991.	
		SEN et al., "Antioxidant and redox regulation of gene trancription," *FASEB J. 10*: 709-720, 1996.	
		SLOMCYZNSKA et al., "Electrochemical Cyclization of Dipeptides To Form Novel Bicyclic, Reverse-Turn Peptidomimetics. 2. Synthesis and Conformational Analysis of 6,5-Bicyclic Systems," *J. Org. Chem. 61*(4): 1198-1204, 1996.	
		SONGYANG et al., "Use of an oriented peptide library to determine the optimal substrates of protein kinases," *Current Biology 4*(11): 973-982, 1994.	
		TERNANSKY et al., "[3.3.0] Pyrazolodinones: An Efficient Synthesis Of A New Class Of Synthetic Antibacterial Agents," *Tetrahedron Letters 31*(20): 2805-2808, 1990.	

Examiner Signature	/Phyllis Spivack/	Date Considered	05/23/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./